Related Experiment Video
Updated: Jul 30, 2025
06:51
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
7.7K
First-line immunosuppression in neuromuscular diseases
Michael A Foster1,2, Michael Pt Lunn3,4, Aisling S Carr3,4
1UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK m.a.foster@ucl.ac.uk.
Practical Neurology
|May 12, 2023
Summary
This study outlines a consensus approach for first-line immunosuppression in autoimmune neuromuscular diseases. It guides neurologists on drug selection, dosing, and monitoring to maximize recovery while minimizing risks.
Area of Science:
- Neurology
- Immunology
Background:
- Autoimmune neuromuscular diseases cause peripheral nervous system dysfunction.
- Suboptimal management leads to significant disability.
- Effective treatment requires careful patient and drug selection, counseling, and monitoring.
Purpose of the Study:
- To summarize a departmental consensus on first-line immunosuppression for autoimmune neuromuscular diseases.
- To provide guidance on initiating, dosing, and monitoring commonly used immunosuppressive drugs.
- To enhance clinical recovery and minimize iatrogenic risks.
Main Methods:
- Consensus review of multispecialty evidence and expertise.
- Focus on autoimmune neuromuscular diseases.
- Guidance development for corticosteroids, steroid-sparing agents, and cyclophosphamide.
Main Results:
- Detailed recommendations for starting, dosing, and monitoring immunosuppressive therapies.
- Emphasis on monitoring clinical efficacy to guide treatment adjustments.
- Principles applicable to broader immune-mediated neurological disorders.
Conclusions:
- A structured approach to first-line immunosuppression optimizes outcomes in autoimmune neuromuscular diseases.
- Careful drug selection and monitoring are crucial for maximizing efficacy and safety.
- The outlined principles offer a framework for managing immune-mediated neurological conditions.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
207
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
207
01:15Myasthenia Gravis: Diagnostic Tests
1.1K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.1K
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
469
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
469
01:26Chemical Synapses
8.9K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.9K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
525
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
525